000			02997nam a22003495i 4500
001			81255
003			ES-MaUEC
005			20240119142143.0
007			cr nn 008mamaa
008			141027s2015 gw | s |||| 0|eng d
020			_a9783319098012
040			_aES-MaUEC
050		4	_aRC271.C5 _bR475 2015 EB
245	0	0	_aResistance to Targeted ABC Transporters in Cancer _cedited by Thomas Efferth
260			_aCham, Switzerland _bSpringer _c2015
300			_a1 recurso en línea (X, 300 p.) 60 il., 21 il. col.
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	1		_aResistance to Targeted Anti-Cancer Therapeutics _x2196-5501 _v4
520			_aThis volume covers the most current topics relevant to ABC transporters and resistance to novel and established anticancer drugs, prognosis of patients to compounds to modulate multidrug resistance, compounds used in photodynamic therapy, tyrosine kinase inhibitors and others. Furthermore, the potential of radiopharmaceuticals for diagnosis of multidrug-resistant tumors is also discussed. The development of resistance is a major obstacle in cancer chemotherapy since decades. Drug resistance may develop during repeated treatment cycles after initially successful therapy (acquired or secondary resistance). Alternatively, tumors may be resistant from the beginning (inherent or primary resistance). The failure of chemotherapy is a major reason for the fatal outcome of tumor diseases in many patients. Even worse, tumors frequently develop not only resistance to single drugs, but also to many others at the same time. This phenomenon was termed multidrug resistance and decreases the success rates of therapy regimens with combinations of structurally and functionally different drugs. The uncommonly broad spectrum of anticancer agents that are transported by ABC transporters makes these proteins exquisite targets to search for compounds that inhibit their transport function. A huge amount of compounds from many pharmacologically established drug were observed to inhibit ABC transporters and to reverse multidrug resistanceâ€{u1B2C} of these topics and more is explored in this volume.
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGER
650		4	_aCáncer _xQuimioterapia _0comprobar BNE19951018561 _9674463
700	1		_aEfferth, Thomas _eeditor literario _993589 _0Local
830		0	_aResistance to Targeted Anti-Cancer Therapeutics _x2196-5501 _v4 _9133185
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-09801-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783319098012
907			_a.b12898454 _b10-10-17 _c18-01-16
998			_am _a_alco _a_vill _b10-03-17 _cm _dz _eo _feng _ggw _h0
945			_aRC271.C5 R475 2015 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11568070 _z06-04-17
999			_c81255 _d81255 _x1